Diakonos Oncology

Focus: Diakonos Oncology is a Houston-based immuno-oncology biotech focused on dendritic cell therapies for solid tumors. The company operates at pre-revenue stage with an early-stage pipeline in oncology.

Oncology

Profile data last refreshed Yesterday · AI intelligence enriched 2w ago

Open Jobs

About Diakonos Oncology

AI assessmentNot Hiring

No open roles listed right now. Follow Diakonos Oncology to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Early-stage

3 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

Autologous DC Therapy

Pancreatic Adenocarcinoma

Phase 1

Clinical Trials (1)

NCT04157127Th-1 Dendritic Cell Immunotherapy Plus Standard Chemotherapy for Pancreatic Adenocarcinoma

Phase 1

Help build intelligence for Diakonos Oncology

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Focused pipeline in immunotherapy with DOC1021 advancing in Phase 2 glioblastoma trials, offering exposure to high-value oncology research
Dendritic cell therapy platform represents differentiated modality with fewer competitors than checkpoint inhibitors
Early-stage company offers hands-on involvement in drug development and potential equity upside as programs advance

Watch Out For

No active job openings currently listed suggests minimal near-term hiring or potential organizational constraints
Pre-revenue status with undisclosed funding creates uncertainty around runway and long-term financial stability
Only 3 trials across entire pipeline with no Phase 3 programs indicates significant development risk and time to value

Generated by Claude from Diakonos Oncology's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

DOC1021

Refractory Melanoma

Phase 1/2

Clinical Trials (1)

NCT07288112DOC1021 Dendritic Cell Immunotherapy for Refractory Melanoma

Phase 1/2

DOC1021

Glioblastoma (GBM)

Phase 2

Clinical Trials (1)

NCT06805305DOC1021 Dendritic Cell Immunotherapy for Treatment of Newly Diagnosed Adult Glioblastoma (GBM)

Phase 2

Open Jobs (0)

No open positions listed yet.

Interview Prep Quick Facts

Portfolio: 3 clinical trials

Top TAs: Oncology

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo

Therapeutic Area Focus

Oncology

3 pipeline

Marketed

Pipeline